Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β‐hydroxysteroid dehydrogenase type‐1 inhibitor BMS‐823778

AIMS: BMS‐823778 is an inhibitor of 11β‐hydroxysteroid dehydrogenase type‐1, and thus a potential candidate for Type 2 diabetes treatment. Here, we investigated the metabolism and pharmacokinetics of BMS‐823778 to understand its pharmacokinetic variations in early clinical trials. METHODS: The metab...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Clin Pharmacol
Autori principali: Cheng, Yaofeng, Wang, Lifei, Iacono, Lisa, Zhang, Donglu, Chen, Weiqi, Gong, Jiachang, Humphreys, William Griffith, Gan, Jinping
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Pharmacogenetics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5736839/
https://ncbi.nlm.nih.gov/pubmed/28850715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13421
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi